Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinocare Inc.
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- Freedom Meditech, Inc.
- Home Diagnostics Inc.
- Nipro Diagnostics, Inc.
- Trividia Health, Inc.
- PTS Diagnostics